These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 29305813)

  • 1. A Simultaneous Mixed-Effects Pharmacokinetic Model for Nefopam, N-desmethylnefopam, and Nefopam N-Oxide in Human Plasma and Urine.
    Mittur A
    Eur J Drug Metab Pharmacokinet; 2018 Aug; 43(4):391-404. PubMed ID: 29305813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of route of administration on the pharmacokinetic behavior of enantiomers of nefopam and desmethylnefopam.
    Chawla J; Le Guern ME; Alquier C; Kalhorn TF; Levy RH
    Ther Drug Monit; 2003 Apr; 25(2):203-10. PubMed ID: 12657915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nefopam pharmacokinetics in patients with end-stage renal disease.
    Mimoz O; Chauvet S; Grégoire N; Marchand S; Le Guern ME; Saleh A; Couet W; Debaene B; Levy RH
    Anesth Analg; 2010 Nov; 111(5):1146-53. PubMed ID: 20971961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative pharmacokinetics and pharmacodynamics of intravenous and oral nefopam in healthy volunteers.
    Aymard G; Warot D; Démolis P; Giudicelli JF; Lechat P; Le Guern ME; Alquier C; Diquet B
    Pharmacol Toxicol; 2003 Jun; 92(6):279-86. PubMed ID: 12787260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of modulated electro-hyperthermia on the pharmacokinetic properties of nefopam in healthy volunteers: A randomised, single-dose, crossover open-label study.
    Lee SY; Kim MG
    Int J Hyperthermia; 2015; 31(8):869-74. PubMed ID: 26507458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, metabolism, and excretion of nefopam, a dual reuptake inhibitor in healthy male volunteers.
    Sanga M; Banach J; Ledvina A; Modi NB; Mittur A
    Xenobiotica; 2016 Nov; 46(11):1001-16. PubMed ID: 26796604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Compartmental pharmacokinetics of nefopam during mild hypothermia.
    Podranski T; Bouillon TW; Riva T; Kurz AM; Oehmke MJ
    Br J Anaesth; 2012 May; 108(5):784-91. PubMed ID: 22331396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of nefopam in elderly, with or without renal impairment, and its link to treatment response.
    Djerada Z; Fournet-Fayard A; Gozalo C; Lelarge C; Lamiable D; Millart H; Malinovsky JM
    Br J Clin Pharmacol; 2014 Jun; 77(6):1027-38. PubMed ID: 24252055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of pharmacokinetics and comparative bioavailability of nefopam 30 mg tablets in twelve fasting healthy Pakistani male young subjects: single-dose, randomized, two-period, two-treatment and two-way cross-over design.
    Ahmad M; Yaqoob M; Murtaza G
    Med Princ Pract; 2012; 21(3):271-6. PubMed ID: 22123270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nefopam Hydrochloride: A Fatal Overdose.
    Seetohul LN; De Paoli G; Drummond G; Maskell PD
    J Anal Toxicol; 2015; 39(6):486-9. PubMed ID: 25855761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, distribution, metabolism, and excretion of the dual reuptake inhibitor [(14)C]-nefopam in rats.
    Yu J; Solon E; Shen H; Modi NB; Mittur A
    Xenobiotica; 2016 Nov; 46(11):1026-48. PubMed ID: 26927982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).
    Zannikos PN; Rohatagi S; Jensen BK; DePhillips SL; Rhodes GR
    J Clin Pharmacol; 2000 Oct; 40(10):1129-40. PubMed ID: 11028252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nefopam enantiomers: preclinical pharmacology/toxicology and pharmacokinetic characteristics in healthy subjects after intravenous administration.
    Mather GG; Labroo R; Le Guern ME; Lepage F; Gillardin JM; Levy RH
    Chirality; 2000 Mar; 12(3):153-9. PubMed ID: 10689295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positive interference of the analgesic nefopam in the urine immunoassay for benzodiazepines in a secure setting.
    Reid KS
    J Psychopharmacol; 2009 Nov; 23(8):997. PubMed ID: 18635712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitive determination of nefopam and its metabolite desmethyl-nefopam in human biological fluids by HPLC.
    Aymard G; Warot D; Demolis P; Laville I; Diquet B
    J Pharm Biomed Anal; 2002 Nov; 30(4):1013-21. PubMed ID: 12408892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Compartmental Analysis for Morphine and Its Metabolites in Young Children After a Single Oral Dose.
    Velez de Mendizabal N; Jimenez-Mendez R; Cooke E; Montgomery CJ; Dawes J; Rieder MJ; Aleksa K; Koren G; Jacobo-Cabral CO; Gonzalez-Ramirez R; Castañeda-Hernandez G; Carleton BC
    Clin Pharmacokinet; 2015 Oct; 54(10):1083-90. PubMed ID: 25773480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nefopam inhibits calcium influx, cGMP formation, and NMDA receptor-dependent neurotoxicity following activation of voltage sensitive calcium channels.
    Novelli A; Díaz-Trelles R; Groppetti A; Fernández-Sánchez MT
    Amino Acids; 2005 Mar; 28(2):183-91. PubMed ID: 15714253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nefopam and ketoprofen synergy in rodent models of antinociception.
    Girard P; Verniers D; Coppé MC; Pansart Y; Gillardin JM
    Eur J Pharmacol; 2008 Apr; 584(2-3):263-71. PubMed ID: 18316069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of nefopam on the gain and maximum intensity of shivering in healthy volunteers.
    Taniguchi Y; Ali SZ; Kimberger O; Zmoos S; Lauber R; Markstaller M; Kurz A
    Anesth Analg; 2010 Aug; 111(2):409-14. PubMed ID: 20529984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
    Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.